UTAH MEDICAL PRODUCTS, INC. CONSOLIDATED CONDENSED STATEMENT OF CASH FLOW (USD $) In Thousands, unless otherwise specified	9 Months Ended
	Sep. 30, 2014	Sep. 30, 2013
Statement of Cash Flows
Net income	$ 8,378	$ 7,938
Adjustments to reconcile net income to net cash provided by operating activities:
Depreciation	474	459
Amortization	2,064	1,914
(Gain) loss on investments	0	0
Provision for (recovery of) losses on accounts receivable	(26)	5
(Gain)/Loss on disposal of assets	4	6
Deferred income taxes	(414)	(567)
Stock-based compensation expense	49	21
Changes in operating assets and liabilities:
Accounts receivable	(291)	(489)
Accrued interest and other receivables	(50)	(170)
Inventories	(99)	(205)
Prepaid expenses and other current assets	22	19
Accounts payable	258	226
Accrued expenses	489	315
Deferred revenue	0	(75)
Other liability	0	(339)
Total adjustments	2,480	1,120
Net cash provided by operating activities	10,858	9,058
Capital expenditures for property and equipment	(953)	(222)
Capital expenditures for intangible assets	0	(5)
Purchases of investments	0	0
Proceeds from sale of investments	0	0
Net cash provided by (used in) investing activities	(953)	(227)
Proceeds from issuance of common stock - options	361	647
Common stock purchased and retired	(1,017)	0
Payment of taxes for exchange of stock options	0	(90)
Tax benefit attributable to exercise of stock options	139	241
Repayment of notes payable	(3,052)	(2,909)
Payment of dividends	(1,874)	(1,824)
Net cash provided by (used in) financing activities	(5,443)	(3,935)
Effect of exchange rate changes on cash	(609)	103
Net increase in cash and cash equivalents	3,853	4,999
Cash at beginning of period	14,395	8,871
Cash at end of period	18,248	13,870
Cash paid during the period for income taxes	2,492	2,662
Cash paid during the period for interest	$ 239	$ 341